<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43688">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095925</url>
  </required_header>
  <id_info>
    <org_study_id>MICA</org_study_id>
    <nct_id>NCT02095925</nct_id>
  </id_info>
  <brief_title>Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism</brief_title>
  <acronym>MICA</acronym>
  <official_title>Microparticle's Procoagulant Activity to Identify Patients With Cancer and a High Risk for Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harry Buller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slotervaart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <authority>The Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism,
      collectively termed venous thromboembolism (VTE). Risk assessment scores for VTE in cancer
      patients have been previously developed by the groups of Khorana and Vienna CATS. However,
      routine thromboprophylaxis for ambulatory cancer patients based on these scores is currently
      not recommended. In the investigators prospective, observational cohort study, the
      investigators aim to identify cancer patients at high risk for VTE based on clinical
      characteristics, coagulation biomarkers and the coagulant activity of tissue factor bearing
      microparticles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>venous thromboembolism</measure>
    <time_frame>6 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objectively confirmed asymptomatic or symptomatic deep venous thrombosis or pulmonary embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>6 months after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cancer</condition>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>cancer patients</arm_group_label>
    <description>Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      citrated plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal
        carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer,
        urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have
        started chemotherapy no more than 3 months ago
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma,
             pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial
             cell carcinoma or lung carcinoma (small cell or non-small cell) who have started
             chemotherapy no more than 3 months ago

          -  Chemotherapy started no more than 3 months ago or within 7 days after enrollment

          -  Aged 18 years or older

          -  Written informed consent

        Exclusion Criteria:

          -  Use of anticoagulants (heparin, vitamin K antagonists or direct oral anticoagulants)

          -  Adjuvant chemotherapy  (i.e. after surgery with curative intent)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nick van Es, MD</last_name>
    <phone>+31205666023</phone>
    <email>n.vanes@amc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <state>Ile-de-France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Mahé, MD</last_name>
      <email>isabelle.mahe@lmr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Mahé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital D'Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello di Nisio, MD PhD</last_name>
      <email>mdinisio@unich.it</email>
    </contact>
    <investigator>
      <last_name>Marcello di Nisio, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Cesarman, MD</last_name>
      <email>gcesarman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela Cesarman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Büller, MD PhD</last_name>
      <email>h.r.buller@amc.nl</email>
    </contact>
    <investigator>
      <last_name>Harrr Büller, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick van Es, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Bleker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU medical center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prabath Nanayakkara, MD PhD</last_name>
      <email>P.Nanayakkara@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Prabath Nanayakkara, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slotervaart hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Martin Otten, MD PhD</last_name>
      <email>Hans-Martin.Otten@slz.nl</email>
    </contact>
    <investigator>
      <last_name>Hans-Martin Otten, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PW Kamphuisen, MD PhD</last_name>
      <email>p.w.kamphuisen@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>PW Kamphuisen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 22, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Harry Buller</investigator_full_name>
    <investigator_title>Harry R Büller, MD PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
